Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gordon, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gordon, M. F.
Related Collections
Right arrow Botulinum toxin
Right arrow All Clinical trials
Right arrow All Cerebrovascular disease/Stroke
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Infarction
NEUROLOGY 2004;63:1971-1973
© 2004 American Academy of Neurology
Brief Communications

Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke

M. F. Gordon, MD, A. Brashear, MD, E. Elovic, MD, D. Kassicieh, DO, C. Marciniak, MD, J. Liu, PhD and C. Turkel, PharmD for the BOTOX Poststroke Spasticity Study Group*

From the North Shore/Long Island Jewish Health Systems (Dr. Gordon), New Hyde Park, NY; Indiana University School of Medicine (Dr. Brashear), Indianapolis, IN; JFK Johnson Rehabilitation Institute (Dr. Elovic), Edison, NJ; Neurological Research Institute of Sarasota (Dr. Kassicieh), FL; Rehabilitation Institute of Chicago (Dr. Marciniak), IL; and Allergan, Inc. (Drs. Liu and Turkel), Irvine, CA.

Address correspondence and reprint requests to Dr. Mark Forrest Gordon, Long Island Jewish Medical Center, 270-05 76th Avenue, New Hyde Park, NY 11040; e-mail: mfgordon{at}lij.edu

The authors evaluated the long-term efficacy and safety of botulinum toxin type A (BTX-A) in poststroke spasticity patients who completed a 12-week placebo-controlled study and received multiple open-label treatments with 200 to 240 U BTX-A for 42 weeks. Significant and sustained improvements were observed for Disability Assessment and Ashworth scores. Adverse events were generally mild. This extension of a double-blind study demonstrates that repeated treatments of BTX-A significantly improve function and tone in spasticity.

Received June 12, 2003. Accepted in final form April 20, 2004.

*Members of the BOTOX Poststroke Spasticity Study Group are listed in the Appendix on page 1973.




This article has been cited by other articles:


Home page
 NeurologyHome page
D. M. Simpson, J-M Gracies, H. K. Graham, J. M. Miyasaki, M. Naumann, B. Russman, L. L. Simpson, and Y. So
Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, May 6, 2008; 70(19): 1691 - 1698.
[Abstract] [Full Text] [PDF]

Home page
 Clin Med ResHome page
S. Ozcakir and K. Sivrioglu
Botulinum Toxin in Poststroke Spasticity
Clin. Med. Res., June 1, 2007; 5(2): 132 - 138.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by AAN Enterprises, Inc.